Core Viewpoint - Cronos Group Inc. is actively engaging in the cannabis industry, focusing on innovative research and product development, and will present at the upcoming ROTH Conference [1][2]. Company Overview - Cronos Group Inc. is a global cannabinoid company dedicated to advancing cannabis research, technology, and product development [2]. - The company aims to build a disruptive intellectual property portfolio and enhance the consumer experience through its brand offerings [2]. - Cronos' brand portfolio includes notable names such as Spinach, PEACE NATURALS, LIT™, and Lord Jones [2]. Upcoming Events - Mike Gorenstein, the Chairman, President, and CEO of Cronos, will speak at the 38th Annual ROTH Conference on March 23, 2026, at 11:30 AM PDT [1]. - A live webcast of the presentation will be available on the company's investor relations website [1].

Core Insights - Cronos Group reported a record year in 2025, with organic net revenue growth of 25% and significant increases in quarterly and full-year metrics, including net revenue, gross profit, and adjusted EBITDA [4][7] - The company achieved a fourth-quarter net revenue of $44.5 million, representing a 47% year-over-year increase, driven by higher cannabis flower and extract sales in various markets [3][7] - Adjusted gross margin for the full year was 43%, although it dipped to 36% in Q4 due to production quality issues related to expansion [2][7] Financial Performance - Fourth-quarter gross profit was $16.2 million, yielding a 36% margin, which improved by 670 basis points compared to Q4 2024 [2] - Consolidated net revenue for Q4 reached $44.5 million, up 47% year-over-year, attributed to increased sales in Israel, Canada, and other countries [3] - The full-year adjusted gross margin was reported at 43%, with management indicating this as a reasonable expectation for future performance [7] Market Expansion - International revenue saw significant growth, with Israel net revenue increasing by 52% and other international markets rising by 68% year-over-year [5][11] - The company is acquiring CanAdelaar for EUR 57.5 million (approximately $67.5 million) to establish a presence in the Netherlands' legal adult-use cannabis market [14][15] - Cronos emphasized strong consumer demand in Canada and ongoing expansion in Israel as key growth drivers [4] Product Development and Brand Performance - Spinach emerged as a leading brand in Canada, becoming the second overall vape brand and the top brand in vape cartridges [6][8] - SOURZ maintained a strong market position in edibles, achieving nearly 22% market share in Q4 [9][10] - The company launched Spinach PUFFERZ, an all-in-one vape device, with broader distribution expected in early 2026 [9] Balance Sheet and Capital Allocation - Cronos ended the quarter with approximately $832 million in cash and no debt, indicating a strong liquidity position [5][17] - The company has an active share repurchase program and plans to continue this strategy while exploring disciplined M&A opportunities [18][19] - Management indicated a lower annual capital expenditure expectation of under $10 million based on current operational needs [21]

Financial Data and Key Metrics Changes - The company reported consolidated net revenue of $44.5 million for Q4 2025, a 47% increase year-over-year, driven by higher cannabis flower and extract sales [15] - Full-year 2025 net revenue grew organically by 25%, with record gross profit and Adjusted EBITDA achieved [5][18] - Adjusted gross profit for Q4 was $16.2 million, equating to a 36% margin, a 670 basis point improvement from the previous year [15] Business Line Data and Key Metrics Changes - In Canada, record quarterly net revenue was up 42% year-over-year, with significant contributions from flower, vapes, and edibles [5] - Spinach became the number 2 overall vape brand in Canada, achieving number 1 market share in vape cartridges [6][9] - In edibles, Spinach maintained a market share approaching 22%, with strong growth driven by new product launches [8] Market Data and Key Metrics Changes - In Israel, net revenue grew 52% year-over-year, marking the 8th consecutive quarter of record net revenue for the company in that market [10] - Internationally, net revenue increased by 68% year-over-year, led by growth in Germany [10] - The company announced plans to acquire CanAdelaar, the largest operator in the Netherlands' legal adult-use cannabis program, for approximately $67.5 million [11] Company Strategy and Development Direction - The company aims to leverage its strong balance sheet and self-sustaining business model to continue its share repurchase program while exploring M&A opportunities [19] - The acquisition of CanAdelaar is seen as a strategic move to establish a foothold in the Netherlands, a key market for adult-use cannabis [20] - The focus remains on delivering sustainable top-line growth and maintaining disciplined cost management as the company scales globally [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operating leverage of the business as production stabilizes and scale efficiencies are realized [16] - The company anticipates continued momentum in 2026, driven by increased production capacity and growth in branded products [20] - Management highlighted the importance of innovation, particularly in product categories like vapes and edibles, to maintain competitive advantage [7][44] Other Important Information - The company ended Q4 2025 with $832 million in cash equivalents and short-term investments, allowing for continued investment in growth and innovation [17] - Adjusted EBITDA for Q4 was $0.5 million, an improvement of $7.7 million year-over-year, despite being lower than the first three quarters of 2025 due to gross margin pressures [16] Q&A Session Summary Question: Product allocation from GrowCo capacity - Management indicated that decisions on product allocation balance market demand and margin considerations, with expectations for more consistent supply in 2026 [23][24] Question: Improving gross margins - Management noted that Q4 faced production quality mix challenges and one-time expenses, but expects margins to stabilize around 43% for the full year 2025 [25][29] Question: Revenue timing shifts - Management acknowledged some timing shifts in international markets contributing to revenue beats, but emphasized overall business growth [34] Question: Domestic market drivers - Management attributed the 40% year-over-year growth in Canada to increased supply, allowing the company to meet existing demand [40] Question: Future capital deployment - Management remains committed to the share buyback program while exploring international opportunities and potential new products [41] Question: Innovation trends - Management highlighted ongoing innovation in genetics, edibles, and vapes, with particular excitement around the PUFFERZ product launch [43][44] Question: Strategic focus on the Netherlands over Germany - Management explained that the Netherlands offers a unique opportunity to enter the adult-use market directly, while Germany presents regulatory uncertainties [49][50] Question: Downstream opportunities - Management prefers to be a customer rather than an owner of downstream assets unless long-term stability can be assured [52] Question: Lessons from past acquisition options - Management emphasized the importance of regulatory timing and the need for a disciplined approach to acquisitions in the U.S. market [59][60]

Financial Data and Key Metrics Changes - The company reported consolidated net revenue of $44.5 million for Q4 2025, a 47% increase year-over-year, driven by higher cannabis flower and extract sales [15][5] - Full-year 2025 net revenue grew organically by 25%, with record gross profit and adjusted EBITDA achieved [5][18] - Adjusted gross profit for Q4 was $16.2 million, equating to a 36% margin, a 670 basis point improvement from the previous year [15][16] Business Line Data and Key Metrics Changes - In Canada, record quarterly net revenue increased by 42% year-over-year, with significant contributions from flower, vapes, and edibles [5][9] - Spinach became the second most popular brand in Canada, with notable performance in vapes, achieving the number one market share in vape cartridges [6][7] - SOURZ maintained category leadership in edibles with market share approaching 22%, driven by new product launches [8][9] Market Data and Key Metrics Changes - In Israel, net revenue grew by 52% year-over-year, marking the eighth consecutive quarter of record net revenue for the company in that market [9][10] - Internationally, net revenue increased by 68% year-over-year, led by growth in Germany [10] - The company announced plans to acquire CanAdelaar, the largest operator in the Netherlands' legal adult-use cannabis program, for approximately $67.5 million [11][12] Company Strategy and Development Direction - The company aims to leverage its strong balance sheet and self-sustaining business model to continue its share repurchase program while exploring M&A opportunities [19][20] - The acquisition of CanAdelaar is seen as a strategic move to establish a foothold in the Netherlands, which has a long history of adult-use cannabis sales [12][50] - The focus remains on delivering sustainable top-line growth and maintaining disciplined cost management as the company scales globally [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operating leverage of the business as production stabilizes and scale efficiencies are realized [16][19] - The company anticipates continued momentum in 2026, driven by increased production capacity and growth in branded products [20] - Management highlighted the importance of innovation, particularly in product categories like vapes and edibles, to maintain competitive advantage [7][44] Other Important Information - The company ended Q4 with $832 million in cash equivalents and short-term investments, allowing for continued investment in growth and innovation [14][17] - Adjusted EBITDA for Q4 was $0.5 million, an improvement of $7.7 million year-over-year, despite lower margins due to production quality issues [15][16] Q&A Session Summary Question: Product allocation from new GrowCo capacity - Management indicated that product allocation decisions balance market demand and margin considerations, with expectations for more consistent supply in 2026 [23][24] Question: Future gross margin expectations - Management noted that Q4 faced production quality challenges, but expects margins to stabilize around the full-year 2025 levels moving forward [25][29] Question: Revenue growth drivers in Canada - Management attributed the growth to increased supply and the ability to meet existing demand in the market [40] Question: Current pipeline of potential opportunities - Management emphasized commitment to the buyback program while exploring international expansion and new product opportunities [41][42] Question: Innovation trends and product launches - Management highlighted ongoing innovation in genetics, edibles, and vapes, with particular excitement around the PUFFERZ product launch [43][44] Question: Strategic focus on the Netherlands versus Germany - Management explained that the Netherlands offers a unique opportunity to enter the adult-use market directly, while Germany presents regulatory uncertainties [48][50] Question: Downstream opportunities in the cannabis market - Management prefers to evaluate downstream opportunities on a case-by-case basis, focusing on long-term viability and regulatory stability [51][52] Question: Lessons learned from past acquisition options - Management reflected on the importance of being disciplined and cautious in pursuing acquisitions, particularly in the context of regulatory changes [59][60]

Core Viewpoint - Cronos Group Inc. will hold its 2025 fourth quarter and full-year earnings conference call on February 26, 2026, at 8:30 a.m. ET, where senior management will discuss financial results and answer questions from the investment community [1]. Group 1 - Participants can register for the conference call or webcast online and are encouraged to join fifteen minutes early to avoid delays [2]. - The webcast will be archived for replay on the Company's website [2]. Group 2 - Cronos is a global cannabinoid company focused on advancing cannabis research, technology, and product development, aiming to build a disruptive intellectual property portfolio [3]. - The Company is committed to enhancing the consumer experience and developing an iconic brand portfolio, which includes brands like Spinach, PEACE NATURALS, and Lord Jones [3].

Core Insights - Cronos Group Inc. achieved record levels of consolidated net revenue, gross profit, and Adjusted EBITDA in Q3 2025, with net revenue increasing by 9% quarter-over-quarter and 6% year-over-year [1][2] - The company reported record-high net revenue in Israel, where its PEACE NATURALS brand remains the number one cannabis brand [1][2] - Cronos Group maintains a strong balance sheet with $824 million in total cash and cash equivalents and short-term investments [1][3] Financial Performance - Net revenue for Q3 2025 was $36.3 million, an increase of $2.1 million from Q3 2024, primarily driven by higher cannabis flower sales in Israel and cannabis extract sales in Canada [10] - Gross profit for Q3 2025 was $18.3 million, up $14.7 million from Q3 2024, attributed to lower inventory step-up costs and higher average sales prices [10][7] - Adjusted EBITDA improved to $5.7 million in Q3 2025, an increase of $11.7 million from Q3 2024, driven by higher gross profit and lower operating expenses [10][7] Market Position - The Spinach brand ended Q3 2025 as the second most popular brand in Canada, holding a 4.5% total market share, and ranked 1 in edibles with a 19.7% market share [11][12] - PEACE NATURALS continues to be the top-performing brand in Israel, achieving record net revenue and sales volume in Q3 2025 [15][16] - International results outside of Israel were modest due to shipment timing, with expectations for second-half performance to align closely with the first half [16] Brand and Product Updates - The Spinach brand launched new products, including SOURZ by Spinach Fully Blasted gummies and limited-edition flavors, reinforcing its leadership in innovative cannabis edibles [12] - Cronos Group's expansion of Cronos GrowCo is complete, with sales from the expansion expected to fuel growth in 2026 [17] - The company introduced new strains under the PEACE NATURALS brand in Israel, reflecting its advanced genetic breeding program and cultivation capabilities [15]

Core Viewpoint - Cronos Group Inc. will hold its third quarter earnings conference call on November 6, 2025, at 8:30 a.m. ET to discuss financial results and answer questions from the investment community [1]. Company Overview - Cronos is a global cannabinoid company focused on advancing cannabis research, technology, and product development, aiming to build a disruptive intellectual property portfolio [3]. - The company is committed to enhancing the consumer experience and developing an iconic brand portfolio, which includes brands like Spinach, PEACE NATURALSand Lord Jones [3]. Conference Call Details - Participants can register for the conference call or webcast online and are encouraged to join fifteen minutes early to avoid delays [2]. - The webcast will be archived for replay on the company's website [2]. Contact Information - For investor relations, Harrison Aaron can be contacted at (416) 504-0004 or via email at investor.relations@thecronosgroup.com [5].

Core Insights - Cronos Group Inc. reported a 21% year-over-year increase in net revenue for Q2 2025, reaching $33.5 million, driven by strong sales in Israel and international markets [1][10] - The company maintains a robust balance sheet with $834 million in cash and cash equivalents, providing flexibility for future growth and expansion [1][3] - PEACE NATURALS remains the leading cannabis brand in Israel, achieving record revenue and sales volume due to high demand for medical cannabis [1][16] Financial Performance - Net revenue for Q2 2025 was $33.5 million, an increase of $5.7 million from Q2 2024, attributed to higher cannabis flower sales and the consolidation of Cronos GrowCo [10] - Gross profit for Q2 2025 was $14.5 million, up 130% from the previous year, reflecting improved sales prices and production efficiencies [10][6] - The net loss for Q2 2025 was $38.5 million, a significant increase from the previous year's loss, primarily due to foreign exchange losses [10][36] Market Position and Strategy - Cronos Group's international strategy has led to significant margin improvements, with strong performance in the Canadian market despite supply constraints [2][3] - The Spinach brand achieved a 4.7% market share in Canada, while Lord Jones and PEACE NATURALS continue to perform well in their respective segments [11][14][16] - The company is expanding its presence in international markets, launching PEACE NATURALS in Australia, Malta, and Switzerland [17] Operational Developments - The expansion of Cronos GrowCo is complete, with expected sales contributions beginning in Fall 2025, aimed at fueling growth in both domestic and international markets [18] - Cronos Group made a strategic investment of approximately $18.5 million in High Tide Inc., enhancing its competitive position in the Canadian cannabis retail market [21] Brand Performance - The Spinach brand's gummies maintained a 19.9% market share in the edibles category, showcasing strong consumer loyalty [12] - Lord Jones Chocolate Fusions™ captured a 10.2% market share, reinforcing its position as a leading brand in the chocolate cannabis edible segment [14] - PEACE NATURALS continues to thrive in Israel, supported by advanced cultivation techniques and a strong operational team [16]

Core Viewpoint - Cronos Group Inc. is set to hold its second quarter earnings conference call on August 7, 2025, at 8:30 a.m. ET, where senior management will discuss financial results and answer questions from the investment community [1]. Group 1 - The conference call will be accessible via online registration, and participants are encouraged to join fifteen minutes early to avoid delays [2]. - Cronos is described as an innovative global cannabinoid company focused on advancing cannabis research, technology, and product development [3]. - The company aims to build a diverse and iconic brand portfolio, which includes brands like Spinach, PEACE NATURALS, and Lord Jones [3].

Core Points - Cronos Group Inc. is an innovative global cannabinoid company focused on advancing cannabis research, technology, and product development [2] - The company is committed to building a diverse international brand portfolio, which includes brands like Spinach, PEACE NATURALS, and Lord Jones [2] - Mike Gorenstein, the Chairman, President, and CEO of Cronos, will speak at the TD Cowen 9th Annual Future of the Consumer Conference on June 4, 2025 [1] Company Overview - Cronos Group is dedicated to creating disruptive intellectual property in the cannabis sector [2] - The company aims to responsibly enhance the consumer experience through its brand portfolio [2] - More information about Cronos and its brands can be found on their official website [2]